Does acyclovir therapy cause diabetes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Acyclovir Does Not Cause Diabetes

No, acyclovir use does not cause diabetes. There is no evidence in the medical literature, FDA drug labeling, or clinical guidelines linking acyclovir to the development of diabetes mellitus.

Key Evidence

FDA Drug Label Findings

The official FDA drug label for acyclovir 1 lists extensive adverse reactions from both clinical trials and post-marketing surveillance. Diabetes, hyperglycemia, or any glucose metabolism disorders are notably absent from this comprehensive list. The most common adverse events include:

  • Nausea/vomiting (2.7% in short-term use)
  • Diarrhea (2-3%)
  • Malaise
  • Headache

The serious adverse effects documented are primarily:

  • Renal toxicity (elevated creatinine, renal failure)
  • Neurological effects (confusion, seizures, encephalopathy - particularly in elderly or renally impaired patients)
  • Hematologic abnormalities

Why This Question May Arise

The confusion likely stems from antiretroviral medications used in HIV treatment, which are completely different drug classes:

The guidelines for HIV treatment 2, 3, 2, 3, 2 extensively discuss hyperglycemia and new-onset diabetes associated with protease inhibitors (PIs) and highly active antiretroviral therapy (HAART), reporting:

  • 3-17% incidence of hyperglycemia in patients on PI therapy
  • 5% incidence of new-onset hyperglycemia over 5 years
  • Median onset ~60 days after PI initiation

This is NOT acyclovir. Acyclovir is an antiviral nucleoside analog used for herpes simplex and varicella zoster infections, while protease inhibitors are antiretroviral agents for HIV.

Interesting Paradox: Acyclovir May Actually Help Diabetes

Emerging research 4 suggests acyclovir may actually improve insulin resistance in diabetic mice by:

  • Activating pyruvate kinase M1 (PKM1)
  • Stimulating AMPK/SIRT1 signaling pathways
  • Reducing blood lipids and oxidative stress
  • Elevating insulin sensitivity

While this is preliminary animal research and not yet applicable to clinical practice, it further reinforces that acyclovir does not cause diabetes.

Clinical Considerations for Diabetic Patients on Acyclovir

If prescribing acyclovir to diabetic patients, the actual concerns are:

Renal function monitoring - Diabetic patients often have baseline renal impairment, and acyclovir can cause nephrotoxicity 1, 5, 6:

  • Dose adjustment required for creatinine clearance <50 mL/min
  • In obese diabetic patients, use ideal body weight or adjusted body weight for dosing (not total body weight) to reduce AKI risk 5
  • Monitor serum creatinine during therapy

Neurotoxicity risk - Enhanced in diabetic patients with renal impairment 6, 7:

  • Presents as confusion, psychiatric changes, seizures, myoclonus
  • Due to accumulation of acyclovir and its metabolite CMMG
  • Requires dose reduction or hemodialysis if severe

Bottom Line

Acyclovir is safe to use in diabetic patients from a glycemic standpoint. Monitor renal function and adjust doses appropriately, but do not withhold this medication due to concerns about diabetes causation - this concern is unfounded and likely represents confusion with antiretroviral medications used in HIV treatment.

Related Questions

What is the recommended dosing regimen for acyclovir in an adult, including oral and intravenous routes and adjustments for renal impairment?
For a 19‑year‑old with type 1 diabetes, weight 86 kg, creatinine 0.74 mg/dL, GFR > 90 mL/min, bicarbonate 17 mmol/L, anion gap 13, currently on metformin 750 mg daily and insulin glargine (Lantus) 15 U at 8 am and 35 U at 8 pm with carbohydrate‑to‑insulin ratios of 1 U per 6 g carbs at breakfast and 1 U per 7 g carbs at lunch/dinner and an insulin‑sensitivity factor of 25 mg/dL per U, and blood glucose values of 184 mg/dL (8 am), 220 mg/dL (noon), 262 mg/dL (5 pm), 237 mg/dL (10 pm), and 97 mg/dL (4 am), what should the morning and evening Lantus doses be and what should the insulin‑sensitivity factor and insulin‑to‑carbohydrate ratios be adjusted to?
For a 19‑year‑old patient with type 1 diabetes weighing 86.2 kg who is currently taking insulin glargine (Lantus) 12 U at 08:00 and 35 U at 20:00 and uses insulin‑to‑carbohydrate ratios of 1 U per 5 g carbs for breakfast and lunch and 1 U per 6 g carbs for dinner, what should the basal Lantus dose and insulin‑to‑carbohydrate ratio be adjusted to?
What is the clinical significance of a +1 glucose result on a urine dipstick and how should it be evaluated?
Can performing 100 repetitions of moderate-to-heavy resistance exercises on large muscle groups every other day for 15 minutes improve insulin sensitivity and help manage pre-diabetes?
Is the rash associated with scabies warm to the touch?
How often does the Rapid Plasma Reagin (RPR) titer fluctuate?
Is West Nile virus contagious via person-to-person transmission?
Should a stable lumbar compression fracture be referred to an orthopedic spine specialist?
When is buddy taping indicated for a toe injury?
What is the therapeutic goal for stool frequency and consistency when titrating lactulose?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.